Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial

Journal of Diabetes & Metabolic Disorders

Fatheya F. AlAwadi⁴  Salah Abusnana³  Mohamed Elhassan Abdalla¹  Puja Thadani⁴  Ahmed Tarig Eltinay²  Elamin Ibrahim Elamin Abdelgadir⁴  Azza Abdulaziz Khalifa Bin Hussain⁴  Alaaeldin M. K. Bashier⁴ 

[1] Sharjah University, Sharjah, UAE;Internal Medicine, Dubai Hospital, Dubai, UAE;RCDR Centre, Ajman, UAE;Endocrine Division, Dubai Hospital, Dubai, UAE

关键词: Type2 diabetes mellitus;    Blood pressure;    Weight;    HbA1c;    Arab population;    Liraglutide;   

Others  :  1212317
DOI  :  10.1186/s40200-015-0178-6

 received in 2015-01-20, accepted in 2015-05-23,  发布年份 2015

【 摘 要 】

Background

The pathophysiology of type2 diabetes differs between different ethnic groups. Asians develop type2 diabetes at younger age, lower body mass index, and in relatively short time. Not only that, some ethnicities have different responses and dosing regimens to different classes of anti-diabetic agents. Data from Japanese population showed that the optimal doses of liraglutide used are smaller than other population and that weight loss is not as effective as seen in Caucasians.

Methods

We aimed to assess liraglutide efficacy in reducing weight and HbA1c in Arab population when used as add on to other anti-diabetic agents. We prospectively followed patients who were recruited to treatment with liraglutide for a 6 months period; at the start of the study we checked patients’ demographics, weight, blood pressure, fasting blood glucose, HbA1c, lipid panel, LFTs and creatinine. Patients were checked at 3 months and at the end of the study at 6 months.

Results

There was a significant reduction in weight at 3 and 6 months from a mean weight of 96.01 ± 19.2 kg to (94.8 ± 20 kg with (P < 0.001)) and 94.5 ± 19 kg with (p < 0.001) respectively. Mean HbA1c at baseline was 8.3 ± 1.7 % dropped to 7.7 ± 1.4 % (p < 0.001) at 3 months, and 7.6 + 1.6 % (p < 0.001) at 6 months.

Conclusions

Liraglutide is effective in reducing weight, HbA1c as well as other metabolic parameters in Arab population with type2 diabetes.

Trial registration

The trial is approved and registered with the Institutional Ethical Committee Board (Dubai Health Authority Medical Research Committee) under registration Number (MRC-08/2013_03).

【 授权许可】

   
2015 Bashier et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal α-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med. 1970; 283:109-15.
• [2]Dunning BE, Gerich JE. The role of α-cell dys-regulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev. 2007; 28:253-83.
• [3]Matsumoto S, Yamazaki M, Kadono M, Iwase H, Kobayashi K, Okada H et al.. Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes. J Clin Biochem Nutr. 2013; 53(1):68-72.
• [4]Seino Y, Rasmussen MF, Katayama Y, Kaku K. The human GLP-1 analogue liraglutide given once daily provides excellent metabolic control in Japanese patients either as monotherapy or in combination with SU during 52 weeks of treatment. Diabetologia. 2009; 52 Suppl 1:S292.
• [5]Ramachandran A, Ma RCW, Snehalatha C. Diabetes in Asia. Lancet. 2010; 375:408-18.
• [6]Seino Y. Relevance of incretins in the treatment of Asian patients with Type2 diabetes. Diab Res Clin Pract. 2008; 79:S4.
• [7]Seino Y, Rasmussen MF, Katayama Y, Kaku K. Liraglutide is statistically superior to glibenclamide at controlling glycemia and weight, with low hypoglycemic risk, and improves beta-cell function in Japanese subjects with T2D. [Abstract 536-P]. 2009.
• [8]Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose dependent improvement in glycaemia with once-daily liraglutide without hypoglycemia or weight gain: a double blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diab Res Clin Pract. 2008; 81:161-8.
• [9]Khalil AB, Beshyah SA, Benbarka MM, Jeanette DB, Roos B. The effect of sitagliptin therapy in suboptimally controlled metformin-treated type 2 diabetes patients: a Middle Eastern experience. Int J Diabetes Metab. 2010; 18:55-8.
• [10]Standards of care in diabetes. Diabetes Care. 2014; 37 Supplement 1:14-80.
• [11]Sethi BK, Viswanathan V, Kumar A, Chatterjee S, Chandalia HB. Liraglutide in clinical practice: insights from LEAD programme. JAPI. 2010; 58:18-22.
• [12]Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type2 diabetes. Curr Med Res Opin. 2010; 26(5):1013-22.
• [13]Yuya F, Norikazu M*, Kana I, Susumu K, Hitoshi N, Ayumu H et al.. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012; 11:107. BioMed Central Full Text
• [14]Melva L, Madoka T, Takeuchi M, Nafrialdi, Rianto S. Incretin-based therapies for type 2 diabetes mellitus in Asian patients: analysis of clinical trials. Med J Indones. 2010; 19:205-12.
• [15]Kendall DM, Riddle MC, Rosenstock J, Zuang D, Kim DD, Fineman MS et al.. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diab Care. 2005; 28:1083-91.
• [16]Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX et al.. Obesity and cardiovascular disease, pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006; 26:968-76.
• [17]Backman L, Freyschuss U, Hallberg D, Melcher A. Reversibility of cardiovascular changes in extreme obesity. Effects of weight reduction through jejunoileostomy. Acta Med Scand. 1979; 205:367-73.
• [18]Backman L, Freyschuss U, Hallberg D, Melcher A. Cardiovascular function in extreme obesity. Acta Med Scand. 1973; 193:437-46.
• [19]Sanjoy P, Kerenaftali K, David M, Jennie B. The association of the treatment with glucagon-like peptide-1 receptor exenatide or insulin with cardiovascular outcomes in patients with type2 diabetes: a retrospective study. Cardiovasc Diabetol. 2015; 14:10. BioMed Central Full Text
• [20]Plutzky J, Garber AJ, Falahati A, Toft AD, Poulter NR. The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials. Eur Heart J. 2009; 30 Suppl 1:917.
• [21]Kana I, Norikazu M, Yuya F, Shiro F, Hirofumi N, Masaya Y et al.. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol Metab Syndr. 2014; 6:95. BioMed Central Full Text
• [22]Fonseca V, Falahati A, Zychma M, Madsbad S, Plutzky J. A meta-analysis of six clinical trials demonstrates that the once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure. Diabetologia. 2009; 52 Suppl 1:S299.
• [23]Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H et al.. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013; 15(8):737-49.
• [24]Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocr. 2014; 46(3):406-19.